Literature DB >> 15971123

Molecular mechanism of the inhibitory effect of trilinolein on endothelin-1-induced hypertrophy of cultured neonatal rat cardiomyocytes.

Shi-Chung Chen1, Jun-Jack Cheng, Ming-Hsiung Hsieh, Yen-Ling Chu, Pai-Feng Kao, Tzu-Hurng Cheng, Paul Chan.   

Abstract

Trilinolein, isolated from the traditional Chinese herb Sanchi ( Panax notoginseng), has been shown to have myocardial protective effects via its antioxidant ability. However, the cellular and molecular mechanisms of the protective effect of trilinolein in the heart remain to be elucidated. Oxidative mechanisms have been implicated in neonatal cardiomyocyte hypertrophy. We therefore have examined whether trilinolein attenuates reactive oxygen species (ROS) production and thus ET-1-induced hypertrophy of cardiomyocytes. Cultured neonatal rat cardiomyocytes were stimulated with ET-1 (10 nM), [3H]leucine incorporation and the beta-myosin heavy chain (beta-MyHC) promoter activity were examined. Trilinolein (1 and 10 microM) inhibited the ET-1-induced increase of [3H]-leucine incorporation in a concentration-dependent manner. Trilinolein (1 and 10 microM) also inhibited ET-1-induced beta-MyHC promoter activity in cardiomyocytes. We further examined the effects of trilinolein on ET-1-induced intracellular ROS generation by measuring a redox-sensitive fluorescent dye, 2',7'-dichlorofluorescin diacetate, fluorescence intensity. Trilinolein (1 and 10 microM) inhibited ET-1-increased intracellular ROS levels in a concentration-dependent manner. This increase of ROS by ET-1 (10 nM) or H2O2 (25 microM) was significantly inhibited by trilinolein (10 microM) and N-acetylcysteine (10 mM). Moreover, ET-1- or H2O2-induced beta-MyHC promoter activity and protein synthesis were also inhibited by trilinolein (10 microM). These data indicate that trilinolein inhibits ET-1-induced beta-MyHC promoter activity, and subsequent hypertrophy via its antioxidant ability in cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15971123     DOI: 10.1055/s-2005-864153

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  5 in total

Review 1.  Therapeutic potential of ginseng in the management of cardiovascular disorders.

Authors:  Morris Karmazyn; Melissa Moey; Xiaohong Tracey Gan
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

2.  Panax notoginseng saponins promote wound repair of anterior cruciate ligament through phosphorylation of PI3K, AKT and ERK.

Authors:  Lu Yu; Jingwei Xie; Na Xin; Zhanyou Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  Protective effects of panax notoginseng saponins on cardiovascular diseases: a comprehensive overview of experimental studies.

Authors:  Xiaochen Yang; Xingjiang Xiong; Heran Wang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-24       Impact factor: 2.629

4.  Panax notoginseng saponins promote liver regeneration through activation of the PI3K/AKT/mTOR cell proliferation pathway and upregulation of the AKT/Bad cell survival pathway in mice.

Authors:  Hua Zhong; Hao Wu; He Bai; Menghao Wang; Jian Wen; Jianping Gong; Mingyong Miao; Fangchao Yuan
Journal:  BMC Complement Altern Med       Date:  2019-06-10       Impact factor: 3.659

5.  Sanqi panax notoginseng injection for angina pectoris.

Authors:  Xiaochen Yang; Xingjiang Xiong; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-16       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.